Familial hypercholesterolaemia (FH), is an autosomal dominant genetic disorder being characterized by the severe hypercholesterolaemia along with cholesterol deposits in tendons and premature heart disease. FH further classified into two homozygous and heterozygous forms.
This specific ailment is caused by a mutation in the gene for the LDL cholesterol receptor, which is involved in passing LDL from the body. It had also been observed that the mutations in some other genes such as PCSK9 and Apolipoprotein B gene can also cause inherited high cholesterol as these all three genes are connected with each other. It is also worth mentioning here that the probability of getting affected with FH is increased due to the inheritance of a specific type of mutation in any of these three genes.
Visit For Sample Pages:
The Familial Hypercholesterolemia market report aslo covers emerging drugs, current treatment practices, Familial Hypercholesterolemia market share of the individual therapies, current and forecasted Familial Hypercholesterolemia Market Size from 2017 to 2030 segmented by seven major markets. The report provides a detailed current Familial Hypercholesterolemia treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Familial Hypercholesterolemia Market Key Facts
As per World Health Organization, the prevalence of elevated cholesterol is highest in Europe (54% for both males and females) which is followed by the America (48% for both males and females).
As per the estimates provided by NORD (National Organisation for Rare Disorders) the worldwide prevalence of HoFH (homozygous familial hypercholesterolaemia) across populations is generally estimated to be 1 in 160,000 to 1 in 1 million.
According to the estimates provided by the National Institute for Health and Clinical Excellence, the reported prevalence of heterozygous familial hypercholesterolaemia in the UK population is estimated to be 1 in 500.
According to DelveInsight’s analysis, females are affected more as compared to males, in case of Familial hypercholesterolemia
As per a study “conducted by Sarah D. de Ferranti et al. (2016)”, the estimated overall US prevalence of probable/definite FH was 0.40% or 1 in 250. Furthermore, the study had also reported that FH prevalence in the US is varied by age, being least common in 20 to 29-year-olds and most common in 60 to 69-year-olds.
Key Benefits of Familial Hypercholesterolemia Market Report
Familial Hypercholesterolemia market report provides an in-depth analysis of Familial Hypercholesterolemia Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The Familial Hypercholesterolemia market report will help in developing business strategies by understanding the Familial Hypercholesterolemia Market trends & developments, key players and future market competition that will shape and drive the Familial Hypercholesterolemia market in the upcoming years.
The Familial Hypercholesterolemia market report covers Familial Hypercholesterolemia current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Familial Hypercholesterolemia market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
The Familial Hypercholesterolemia market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Familial Hypercholesterolemia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Familial Hypercholesterolemia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
The Familial Hypercholesterolemia epidemiology section covers insights about historical and current Familial Hypercholesterolemia patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Familial Hypercholesterolemia Drugs Uptake and Key Market Players
The Familial Hypercholesterolemia Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Familial Hypercholesterolemia market or expected to get launched in the market during the study period. The analysis covers Familial Hypercholesterolemia market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of Familial Hypercholesterolemia market is anticipated to change in the coming years owing to incremental healthcare spending across the world and expected launch of emerging therapies. Companies across the globe are thoroughly working towards the development of new treatment therapies for Familial Hypercholesterolemia. Currently, key emerging players, such as Regenxbio, Esperion Therapeutics, The Medicines Company, Gemphire Therapeutics and Lipigon Pharmaceuticals are involved in developing therapies for Familial Hypercholesterolemia
Table of Content
1. Key Insights
2. Executive Summary
3. Familial Hypercholesterolemia Competitive Intelligence Analysis
4. Familial Hypercholesterolemia Market Overview at a Glance
5. Familial Hypercholesterolemia Disease Background and Overview
6. Familial Hypercholesterolemia Patient Journey
7. Familial Hypercholesterolemia Epidemiology and Patient Population
8. Familial Hypercholesterolemia Treatment Algorithm, Current Treatment, and Medical Practices
9. Familial Hypercholesterolemia Unmet Needs
10. Key Endpoints of Familial Hypercholesterolemia Treatment
11. Familial Hypercholesterolemia Marketed Products
12. Familial Hypercholesterolemia Emerging Therapies
13. Familial Hypercholesterolemia Seven Major Market Analysis
14. Attribute Analysis
15. Familial Hypercholesterolemia Market Outlook (7 major markets)
16. Familial Hypercholesterolemia Access and Reimbursement Overview
17. KOL Views on the Familial Hypercholesterolemia Market.
18. Familial Hypercholesterolemia Market Drivers
19. Familial Hypercholesterolemia Market Barriers
21. DelveInsight Capabilities
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
DelveInsight’s Familial Hypercholesterolemia – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Familial Hypercholesterolemia in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States